Decision Analysis of Post-Remission Therapy in Cytogenetically Intermediate-Risk AML
Whether FLT3-ITD, NPM1, and CEBPA mutation statuses were associated with treatment outcomes in patients who had undergone allogeneic hematopoietic cell transplantation (allo-HCT) and chemotherapy for AML was investigated in this retrospective study. Of 332 patients with AML in first complete remission (CR1), 85 had undergone allo-HCT. FLT3-ITD was present in 60 patients, NPM1 in 83, […]
Decision Analysis of Post-Remission Therapy in Cytogenetically Intermediate-Risk AML Read More »
